Cypherpunk Technologies Inc. (NASDAQ:CYPH) — Market Cap & Net Worth
Market Cap & Net Worth: Cypherpunk Technologies Inc. (CYPH)
Cypherpunk Technologies Inc. (NASDAQ:CYPH) has a market capitalization of $49.50 Million ($49.50 Million) as of April 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25920 globally and #4728 in its home market, demonstrating a -12.53% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cypherpunk Technologies Inc.'s stock price $0.87 by its total outstanding shares 56651840 (56.65 Million).
Cypherpunk Technologies Inc. Market Cap History: 2025 to 2026
Cypherpunk Technologies Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $65.72 Million to $49.50 Million (0.00% CAGR).
Cypherpunk Technologies Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cypherpunk Technologies Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CYPH by Market Capitalization
Companies near Cypherpunk Technologies Inc. in the global market cap rankings as of April 19, 2026.
Key companies related to Cypherpunk Technologies Inc. by market ranking:
- BlackRock Inc (NYSE:BLK): Ranked #127 globally with a market cap of $155.79 Billion USD.
- Blackstone Group Inc (NYSE:BX): Ranked #226 globally with a market cap of $96.64 Billion USD.
- KKR & Co LP (NYSE:KKR): Ranked #240 globally with a market cap of $92.35 Billion USD.
- Brookfield Corp (NYSE:BN): Ranked #245 globally with a market cap of $91.10 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #127 | BlackRock Inc | NYSE:BLK | $155.79 Billion | $1052.14 |
| #226 | Blackstone Group Inc | NYSE:BX | $96.64 Billion | $129.08 |
| #240 | KKR & Co LP | NYSE:KKR | $92.35 Billion | $103.60 |
| #245 | Brookfield Corp | NYSE:BN | $91.10 Billion | $46.59 |
Cypherpunk Technologies Inc. Historical Marketcap From 2025 to 2026
Between 2025 and today, Cypherpunk Technologies Inc.'s market cap moved from $65.72 Million to $ 49.50 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $49.50 Million | -24.67% |
| 2025 | $65.72 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 18th, 2026 the market cap of Cypherpunk Technologies Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $49.50 Million USD |
| MoneyControl | $49.50 Million USD |
| MarketWatch | $49.50 Million USD |
| marketcap.company | $49.50 Million USD |
| Reuters | $49.50 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cypherpunk Technologies Inc.
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-… Read more